The PGY2 Oncology residency program provides advanced training for residents in the fields of bone marrow transplantation, malignant hematology, medical oncology, chemotherapy pharmacy operations, and oral chemotherapy clinic. The residents train at Houston Methodist Cancer Center which is accredited by the Commission on Cancer and is an internationally recognized leader in cancer care and offers revolutionary methods of cancer prevention, diagnosis and treatment from leading medical professionals.
Portions of the residency year will be spent working with both academic and private hematology/oncology consult services. Elective experiences include tumor-specific, infectious diseases, nutrition support, palliative medicine, pediatric oncology, and radiation oncology. Longitudinal experiences include malignant hematology clinic, medical oncology clinic, and breast cancer clinic. In addition, residents will be capable of developing and supporting quality improvement and educational initiatives, understanding and conducting research in the field, and committing to continuous self-learning. Training alongside over 50 clinical pharmacists and 20 other residents, the oncology resident will have ample teaching opportunities including providing instruction to doctor of pharmacy students and mentoring PGY1 residents. The resident will provide an ACPE-accredited CE program and can participate in an optional teaching certificate program through the University of Houston College of Pharmacy.
Houston Methodist Hospital (HMH) is a 900+ bed tertiary teaching hospital and is an academic affiliate of Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, New York Presbyterian Hospital, and many colleges of pharmacy. HMH is consistently ranked in multiple specialties by U.S. News and World Report and recognized as the No.1 hospital in Texas and Gulf Coast. HMH is included on Forbes magazine's list of "America's Best Employers".